Long-term rehabilitation training for people with pulmonary arterial hypertension
Official title: Continuous Effect Of Long-Term Rehabilitation Training On Clinical Improvement(TTCI) And Cardiopulmonary Function In Pulmonary Arterial Hypertension Patients- A Multicenter-randomisation Study
Run by RenJi Hospital · NCT07149935 · Data updated 2026-11-12
This program will test whether a year of aerobic and breathing rehabilitation helps adults with pulmonary arterial hypertension improve symptoms and heart-lung fitness while on stable medication.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 104 (estimated) |
| Sponsor | RenJi Hospital Academic / other |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Status | Recruiting |
| Started | September 1, 2024 |
| Main results expected | June 2026 |
| Study ends | December 2026 |
| Registry record updated | September 2, 2025 |
| Trial ID | NCT07149935 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–75 with confirmed pre-capillary PAH (mPAP ≥20 mmHg, PVR >2 WU, PAWP ≤15 mmHg), WHO-FC I–III, on stable PAH-targeted drugs and without recent exercise rehabilitation are ideal candidates.
✕Probably not a fit
People with WHO functional class IV disease, significant respiratory or ischemic heart disease, active severe organ dysfunction, recent syncope, major motor disability, or other listed exclusions are unlikely to benefit from this rehabilitation program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a multicenter, open-label, two-arm interventional study that delivers a year of long-term rehabilitation including aerobic exercise (cycling and treadmill) and inspiratory muscle training. Participants are adults with pre-capillary pulmonary arterial hypertension who are WHO functional class I–III and are on stable targeted PAH therapy. The study measures time to clinical improvement (TTCI) and changes in cardiopulmonary function over 12 months. Outcome comparisons will be made between the two arms to determine the continuous effects of rehabilitation on symptoms, exercise tolerance, and cardiorespiratory fitness.
Why it matters
Potential benefit: If successful, the program could improve exercise tolerance, symptoms, and overall cardiorespiratory fitness for people with PAH.
How similar studies have gone: Previous studies have shown that supervised exercise rehabilitation can be safe and can improve symptoms and quality of life in PAH, though long-term continuous effects remain less well characterized.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients who suffered from pre-capillary PAH (mPAP ≥ 20 mmHg, PVR \> 2 Woods unit, PAWP ≤ 15 mmHg) confirmed by right heart catheterisation. 2. Patients who are in the status of WHO-FC I-III. 3. Patients between 18 and 75 years old 4. Female subjects are not pregnant. 5. Patients are treated with PAH-targeted drugs and are in a stable state and there is no progress of disease). 6. Patients have not received exercise rehabilitation training within six months. Exclusion Criteria: Patients with the following diseases or symptoms: 1. Pulmonary vascular occlusive disease 2. Respiratory diseases 3. Ischaemic heart disease, complex congenital heart disease (e.g., tetralogy of Fallot, etc.), cardiomyopathy, valvular disease 4. Active liver disease 5. Severe kidney disease 6. Motor disorders (e.g. lower limb fracture, ataxia, etc.) 7. Malignant tumour diseases 8. Physical disability 9. Hb ≤ 80g / L 10. Systolic blood pressure ≤85mmHg 11. History of syncope within 3 months 12. History of supraventricular or ventricular arrhythmia at rest within 3 months.
Where it's running
-
Renji Hospital
Shanghai, Shanghai Municipality, China Recruiting
Study contacts
- Study coordinator: Jieyan Shen, PhD
- Email: shenjieyan@renji.com
- Phone: 13701864819
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Levosimendan to see if it helps the heart after PEA in CTEPH
This small randomized trial tests whether giving levosimendan around surgery helps reduce pulmonary artery pressure and support right heart function after pulmonary endarterectomy for CTEPH.
-
Early treatment with inhaled treprostinil for exercise-induced pulmonary hypertension in ILD or CTD
This study tests whether inhaled treprostinil added to standard care can improve exercise-related lung blood flow and function in adults with ILD or CTD who develop pulmonary hypertension during exercise.
-
Brazilian Portuguese version of EmPHasis-10 for pulmonary hypertension
This study tests a Brazilian Portuguese version of the EmPHasis-10 questionnaire to see if it reliably measures quality of life in adults with pulmonary hypertension in Porto Alegre, Brazil.
-
Inhaled mosliciguat for pulmonary hypertension in interstitial lung disease (PH-ILD) patients
This study tests inhaled mosliciguat versus placebo in people with PH-ILD to see if it helps with their condition.
-
Pulmonary Artery Denervation for Pulmonary Hypertension After M-TEER
This study tests whether PADN can help people with pulmonary hypertension after M-TEER compared with standard medical therapy.
-
Risk Factor Assessment for Acute Pulmonary Hypertension Crisis
This study tests how to identify people with pulmonary hypertension who are at risk of a sudden, life-threatening crisis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.